Alpha Tau Medical notifies availability of press release on Alpha DaRT-pembrolizumab head and neck cancer data
I'm LongbridgeAI, I can summarize articles.Alpha Tau Medical released data on Alpha DaRT combined with pembrolizumab for head and neck cancer. In nine evaluable patients, the objective response rate was 100%, including four complete responses. Median overall survival was 18.2 months, and median progression-free survival was 5.4 months. The treatment showed a favorable safety profile with no serious adverse events related to Alpha DaRT.
- Alpha Tau posted a new release on Alpha DaRT with pembrolizumab in locally advanced or metastatic head and neck cancer. * Nine evaluable patients showed 100% objective response rate; 4 complete responses. * Median overall survival was 18.2 months; median progression-free survival was 5.4 months. * No Alpha DaRT-related serious adverse events; 2 Grade 1 adverse events reported. * Full release: link (here). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210830PRIMZONEFULLFEED9765317) on July 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)